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In the European Union, it is estimated that there are 5.5 million individuals with chronic
infection of hepatitis C. Intravenous drug abuse is undoubtedly the key source of
the hepatitis C epidemic in Europe and the most efficient mode of transmission of
HCV infections (primarily due to short incubation time, but also because the virus is
introduced directly into the blood stream with the infected needle). Potentially high-risk
and vulnerable populations in Europe (and the world) include immigrants, prisoners, sex
workers, men having sex with men, individuals infected with HIV, psychoactive substance
users etc. Since there is a lack of direct evidence of clinical benefits of HCV testing,
decisions related to testing are made based on indirect evidence. Clinical practice has
shown that HCV antibody tests are mostly adequate for identification of HCV infection,
but the problem is that this testing strategy does not hit the target. As a result of this
health care system strategy, a large number of infected patients remain undetected or
they are diagnosed late. There is only a vague link between screening and treatment
outcomes since there is a lack of evidence on transmission risks, multiple causes, risk
behavior, ways of reaching screening decisions, treatment efficiency, etc. According to
results of limited number of studies it can be concluded that there is a need to develop
targeted programmes for detection of HCV and other infections, but there also a need
to decrease potential harms.
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SOME FACTS ABOUT HCV PRESENCE
In 2014, 35,321 new cases of hepatitis C were reported from 28 EU/EEA member states, while
a “crude” rate was 8.8 cases per 100,000 population (European Centre for Disease Prevention
and Control, 2013). Out of these cases, 1.3% were classified as acute, 13.3% as chronic, 74.7% as
“unknown,” and 10.7% were not classified. Intravenous drug abuse is undoubtedly the key source of
the hepatitis C epidemic in Europe and the most efficient mode of transmission of HCV infections
(primarily due to short incubation time, but also because the virus is introduced directly into the
blood stream with the infected needle).
The prevalence of HCV among drug addicts is between 60 and 80%which is in direct correlation
to the period of psychoactive substance abuse. This way HCV infection is transmitted 10 times
faster and more efficiently than HIV infection (Mosley et al., 2005; Wang et al., 2016b).
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In the European Union, it is estimated that there are 5.5
million individuals with chronic infection. Intravenous drug use
is the key issue in dispersion of HCV infection in Europe—
national estimates of antibody-prevalence range from 15 to 84%
(European Monitoring Centre for Drugs Drug Addiction, 2016).
Potentially high-risk and vulnerable populations in Europe
(and the world) include immigrants, prisoners, sex workers, men
having sex with men, individuals infected with HIV, psychoactive
substance users etc. (Forouzanfar et al., 2016).
In Serbia, which geographically belongs to the Western
Balkans, the situation is similar to other countries in the
region—epidemiological characteristics of HCV infection have
not been studied reliably since there is no continuous and
comprehensive disease monitoring. Moreover, there are only few
limited studies on socio-economic background of this disease in
Serbia. Regardless the advancement in the disease treatment, it is
of vital importance to have epidemiological and pharmacological
data in order to make the plan of prevention and control more
efficient (Mitrovic et al., 2015).
Based on limited range studies, the prevalence of HCV in
Serbia is higher than 1% (i.e., the estimated prevalence in general
population is 1.13% (95% CI: 1.0–1.26%) (European Centre for
Disease Prevention and Control, 2013), while in Europe it is
about 1.5% (Cooke et al., 2013). In our population, the most
common HCV genotypes are genotype 1 (63%) and genotype
3 (27%), while genotype 2 and 4 account for 7 and 3% of the
cases, respectively. Genotypes 5 and 6 have not been registered
(Mitrovic et al., 2015).
Jakovljević et al. carried out a study in 2013 which compared
the costs of patients with genotypes 1 or 4 (group I) and patients
with genotypes 2 or 3 (group II). It showed that the patients with
genotypes 1 and 4 caused significantly higher direct medical costs
which did not include medicine purchase costs. When the costs
of the consumed pegylated interferon alfa plus ribavirin were
added, the expenses moved toward patients with genotype 2 or
3 infection. Finally, when indirect costs (e.g., lost productivity
costs) were taken into account, the total costs were even 25%
higher among patients with genotype group 2. The conclusion
was that an average patient belonging to either of the groups
incurred e18,121.04 costs per protocol for the treatment period
less than a year (Jakovljevic et al., 2013).
To make a comparison, the estimates from the Health
Protection Agency (HPA) in Great Britain (Hepatitis, 2013)
show, based on the research carried out by the National Institute
for Health and Clinical Excellence (NICE), that the cost of
antiviral treatment of individuals with hepatitis C varies between
£6,246 for those requiring 24-week treatment (mainly genotypes
2 and 3) and £12,741(14,714.80 euros) for those requiring a
standard treatment of 48 weeks (mainly genotype 1) (Ramsay,
2011).
This means that the treatment of an individual infected with
hepatitis C in Great Britain is almost e3,500 cheaper than in
Serbia. From 2006 to 2014, GDP in Serbia ranged from $3,700
to 4,300, while in Great Britain it was $39,5111.
1http://www.penzin.rs/koliko-drzave-sveta-prave-novca-po-stanovniku-a-
koliko-srbija/
The costs given by the HPA are in compliance with the
costs reported in 2011 by the British National Formulary
for peginterferon alfa-2a (Pegasys), peginterferon alfa-2b
(ViraferonPeg), and ribavirin (Copegus, Rebetol) (British
National Formulary, 2015-2016), including the treatment
monitoring costs taken over from Hartwell et al. (2011).
However, the budget impact of HCV treatment has been
significant. Classic treatments resulted in more significant side
effects and they were less effective than newer treatments. The
most important issue (always) is the price. Health stakeholders
should use scientific information to increase the efficiency and
availability of treatment and reduce costs. Some studies show that
the prevalence growths associated with the increase in annual
health cost are, for example, from £82.7m in 2012 to £115m
in 2035. Also, productivity losses were estimated to rise from
between £184 and £367m in 2010 to between £210 and £427 m,
in 2035 (Hepatitis, 2013).
HCV SCREENING AND OUTCOMES
Hepatitis C is an important public health issue not only in Europe
but all around the world, considering high costs associated with
morbidity and mortality (ECDC, 2015; Wang et al., 2016a). The
Global Burden of Disease (GBD) is 42% formortality as a result of
liver cancer caused by hepatitis C. Approximately 700,000 people
die each year from the consequences of this infection (Lozano
et al., 2012).
Monitoring does not always give a clear picture of the situation
in a particular country. For example, it is estimated that 2.2–3.2
million people are chronically infected with hepatitis C in the
USA, but half of them is unaware of that (CDC, 1998).
Despite the limitations of routine monitoring of HCV
infection, the available data clearly indicate that the largest
number of reported cases was associated with drug injecting and
other groups at risk.
There are two kinds of tests typically used to diagnose HCV
infection (Figure 1):
(1) Serological assays that detect antibody to hepatitis C virus
(anti-HCV);
FIGURE 1 | HCV tests.
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(2) Molecular assays that detect, quantify, and/or characterize
HCV RNA genomes
Serological assays can be subdivided into:
(1) Screening tests for anti-HCV such as EIA and CLIA
(Chemiluminescence Immuno Assay).
(2) And supplemental tests such as RIBA (Recombinant
Immunoblot Assay) test.
In the 1980s first generations of serological assays were
developed. The first-generation anti-HCV EIA detected
antibodies 12–26 weeks after exposure to infection, thus creating
a long window period of infectivity. With the second generation
of tests the window period of infectivity was reduced to 10–24
weeks. So far three generations of serological assays have
been developed in order to improve sensitivity and specificity
(Marwaha and Sachdev, 2014). Nowadays, the third-generation
of EIA assays is used to detect antibodies against reconfigured
hepatitis C proteins: C, NS3, and NS4, as well as NS5A antigen
which the previous generation of assays did not contain (Gretch,
1997).
The third-generation EIA brought about a new reduction
in the window period by a week. Despite many attempts to
increase sensitivity of assays, the problem of serology negative but
“infectious” window period remained, which with the second-
generation assays was 82 days (Busch et al., 1995) and with
the third-generation remained around 66 days (Couroucé and
Pillonel, 1996).
Combination antigen-antibody assays were introduced few
years ago, when, two markers of the same infection were detected
at the same time. These assays are called “fourth-generation” or
“antigen-antibody combo” tests. They are suitable for testing in
blood banks where a large numbers of samples need to be tested
in a short period of time. The average window period for these
assays is 26.8 days (CDC, 2013).
RIBA tests are used to confirm a positive enzyme
immunoassay, while the same serum samples can be used.
RIBA use recombinant antigens and synthetic peptides similar
to EIA. They are in immunoblot format, so that they can detect
antibodies for specific proteins.
The test result is reported positive if antibodies to two or
more antigens are detected, inconclusive or indeterminate if
antibodies to one antigen are detected, or negative. These tests
are recommended to be used primarily for patients at low risk
for HCV like volunteer blood donors (Alter et al., 2003; Narciso-
Schiavon et al., 2008). A positive anti-HCV antibody test does
not distinguish between a current and a past infection, but it
indicates the need for further medical evaluation (Fonseca et al.,
2011). Among immunocompromised individuals, serological
tests can have false-negative results, for example with HIV-
infected patients, with patients with renal insufficiency and with
patients with essential mixed cryoglobulinemia caused by HCV
(Alter et al., 2003) (Table 1).
Qualitative molecular tests are based on RT-PCR technique.
These tests have a detection limit of 50 IU/ml and they are used
to confirm viremia and to monitor treatment response2. If the
2Available online at: http://www.hcvguidelines.org/printpdf/12
test result is positive, there is an active infection. Qualitative PCR
tests are also used with EIA negative patients with suspected acute
infection, with patients diagnosed with hepatitis of unknown
cause, as well as with those with known causes of false-negative
results of antibody tests.
Qualitative molecular tests, PCR, and bDNA (branched DNA
assay) are used to monitor anti-HCV treatment (Alter et al.,
2003).
A very significant non-specific alanine aminotransferase
measurement (ALT) test used to monitor infections and
treatment effectiveness should be also mentioned here (Alter
et al., 2003).
The AASLD (American Association of the Study of Liver
Diseases) and the IDSA (Infectious Disease Society of America)
strongly recommend annual HCV testing for persons who inject
drugs and for HIV-seropositive men who have unprotected sex
with men1.
WHAT ABOUT TESTING STRATEGIES?
Since there is a lack of direct evidence of clinical benefits of HCV
testing, decisions related to testing are made based on indirect
evidence (Chou et al., 2012). Furthermore, clinical practice has
shown that HCV antibody tests are adequate for identification
of HCV infection. The problem is that this testing strategy
does not hit the target. As a result of this health care system
strategy, a large number of infected patients remains undetected
or are diagnosed late. Potentially, these patients are permanent
sources of infection, which is very important especially for groups
at risk. This way, our understanding of the actual risks and
the real dimensions of this problem remains incomplete. In
order to make screening more effective, besides strategies to
identify HCV infected individuals, there should be strategies
for further actions including counseling, education, medical
treatment, physiological, and psychiatric support etc., with the
aim to improve treatment outcomes. At this time, there is only
a vague link between screening and treatment outcomes since
there is a lack of evidence on transmission risks, multiple causes,
risk behavior, ways of reaching screening decisions, treatment
efficiency, etc.
Retrospective studies that analyzed strategies that target
several risk factors showed sensitivity of over 90% and the need to
test up to 20 people in order to identify one HCV-infected person
(Gunn et al., 2003; Zuure et al., 2010).
However, there have been no prospective studies to compare
different screening strategies or consider a new (alternative)
approach to screening or possible outcomes. In the USA,
epidemiological data show that about two-thirds of people with
chronic hepatitis C were born between 1945 and 1965. Birth-
cohort screening may be a useful future screening strategy. The
only published birth-cohort is a cost-effectiveness study from
2012 (Rein et al., 2012).
Some studies published in the last decade suggest the
knowledge of being infected reduces risk behavior of some
patients (Hagan et al., 2006; Scognamiglio et al., 2007; Trepka
et al., 2007), but prospective studies show that this behavior is
not sustained over time (Tsui et al., 2009).
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TABLE 1 | Testing for HCV infection.
Test result Interpretation Further action
HCV antibody non-reactive No HCV antibody detected Sample may be non-reactive for HCV antibody. No further action is required. If there was a recent
exposure, test for HCV RNA.
HCV antibody reactive Presumptive HCV infection A repeatedly reactive result indicates current HCV infection, past HCV infection that has resolved or
biologic false positivity for HCV antibody. Test for HCV RNA is order to identify current infection.
HCV antibody reactive Current HCV infection Organize testing with appropriate counseling and link the tested person to future treatment.
HCV RNA detected
HCV antibody reactive No current HCV infection In most cases, no further action is needed.
HCV RNA not detected If there is desired distinction between true positivity and biologic false positivity for HCV antibody, and if
the sample is repeatedly reactive in the initial test, test with another HCV antibody assay.
In certain situations, continue with HCV RNA testing and appropriate counseling.
CDC. Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR 2013; 62 (Gretch, 1997).
Nevertheless, there are many uncertainties concerning
potential harms and benefits of HCV testing. There is a need
to study psychological aspects of testing such as fear, anxiety,
acute stress reaction, impact on quality of life, impact on partner
relationships, family, and social relations, etc. There is also a
question whether a wider concept of counseling would contribute
to reduction of potentially harmful influences of the given factors.
Testing efficiency and cost-effectiveness are present additional
problems. How reasonable is to repeat rapid antibody detection
tests?
Patient testing as part of PAS addiction treatment programmes
is a good way to target chronically infected individuals which
enables implementation of potentially new approaches to
treatment which might become more efficient that the existing
ones (Afdhal et al., 2013; Frimpong, 2013).
A research carried out within the programme for community-
based treatment of addicts by the National Drug Abuse
Treatment Clinical Trials Network (CTN), showed that only
28% of the USA programmes offered HCV testing as part of
their programme or in the nearest reference center (Pollack
and D’Aunno, 2010; Bini et al., 2012). The latest researches
show a significant reduction in HIV and HCV testing within
opiate addiction treatment programmes between 2005 and 2011
and a significant increase of testing within public treatment
programmes (D’Aunno et al., 2014), which suggests that scarce
resources can play an important role in deciding whether to
invest into private-profitable or unprofitable programmes.
Between 2003 and 2014, Serbia received ∼$30 million from
the Global Fund for development and implementation of HIV
and HCV prevention and treatment in Serbia. However, as a
middle income country, Serbia lost the funding abruptly when
its HIV burden was estimated as “moderate” (The Global Fund,
2015). Furthermore, in 2012 Serbia was removed from the list of
countries eligible for support in 2013 (Jakovljevic et al., 2017).
In 26 opiate addiction treatment centers in Serbia, HCV
testing was drastically reduced because they were no longer
financed by the Global Fund. The testing programmes included
rapid tests within the treatment centers or at the nearest reference
centers. Since 2014, the number of tests has been constantly
decreasing (Jakovljević and Jovanović, 2011).
The World Health Organization states that the Global Fund
supports comprehensive harm reduction packages that include
preventive activities, testing and treatment of hepatitis C (World
Health Organization, 2014).
Based on the available evidence, on-site rapid HIV and
hepatitis C testing at addiction treatment centers is an excellent
investment in public health (Jakovljevic et al., 2016).
Legal authorities should identify the ways to improve and
implement on-site HCV and HIV rapid testing at addiction
treatment centers and ensure that the individuals with positive
results proceed to further treatment and further evaluation
(Schackman et al., 2015).
One of major concerns is liver biopsy which is an invasive
procedure with potentially serious adverse effects which is
still the only reliable method to determine the histological
state of the liver in HCV-infected individuals. A possible
alternative would be to develop non-invasive techniques and
tests to determine the stage of the disease (Chou et al., 2012).
However, further comparative studies are needed to determine
the significance of the liver biopsy in relation to further treatment
courses.
There is also the issue of testing and education of specific
groups and the impact of testing on the public health.
Testing and education should not be limited only to groups
at risk such as PAS users, it should include other groups in
need for immunization such as vaccination of alcoholics against
hepatitis A and B and implementation of a knownHCV detection
strategy.
Hepatitis C virus infection is the most prevalent infection
among intravenous drug users. According to the study conducted
in Serbia in 2008, the prevalence among intravenous drug users
was 69% in Belgrade, 50% in Niš, and 45% in Novi Sad.
The same study showed that after voluntary, free of charge
and confidential testing on HCV, HIV and syphilis, more
than 55.3% of the tested individuals in Belgrade and 43.5%
in Niš failed to return for their test results. (Mickovski,
2010). The future studies should take into account the cost
of testing, motivation and other psychological characteristics
of the studied patients, as well as the outcomes of these
interventions.
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Studies conducted in other countries also show that only a
small number of people injecting drugs returns for their results
(Hagan et al., 2006; McDonald et al., 2010). Since this is a high-
risk population, an adequate strategic approach is needed to
enable frequent testing, preferably free of charge and an easy
way to get to an infectologist and further treatment. To be more
precise, testing should be done in places where the therapy is
administered.
Although screening can positively identify adults with chronic
HCV infection, more research is needed to understand the effects
of different screening strategies on the clinical outcome. The
evidence on effects of knowledge of HCV status, counseling,
and vaccination of HCV diagnosed patients are still scarce.
There should also be more studies on interventions that could
successfully prevent vertical transmission. A comprehensive
assessment of benefits and harms of screening includes
evaluation of the effectiveness of antiviral regimes is also
necessary.
Furthermore, there is a need for a cost-effectiveness study
of the fourth-generation HCV antigen and antibody assay
(combination EIA) twoHCV in the same assay.Molecular testing
for HCV-RNA using nucleic acid amplification technology
(NAT) is today the most sensitive assay that shortens the window
period to only 4 days. Implementation of NAT inmany developed
countries in the world has resulted in dramatic reductions in
transfusion transmitted HCV infections, so now the relative risk
is <1 per million donations (CDC, 2013).
If we bear in mind all the facts stated above, it becomes
obvious that future studies will have to consider testing costs in
relation to potential benefits in specific, high-risk populations.
CONCLUSION
The current hepatitis C testing strategy is not efficient, as
concluded by numerous studies.
Research, development, validation, and cost-effectiveness
studies should yield best practices for detecting HCV
viremia and for developing new possibilities to distinguish
between people with resolved HCV infection and those
with biologic false positivity for HCV antibody, in
whom HCV RNA has not been detected. The results of
these studies should provide comprehensive guidelines
for testing, reporting, and clinical management and
improve definitions for disease reporting and surveillance.
(Gregory and Dodd, 2009; Marwaha and Sachdev,
2014).
Based on the presented facts, it can be concluded
that there is a need to develop targeted programmes for
detection of HCV and other infections, but there also a
need to decrease potential harms. Furthermore, public
health programmes have to be made according to the
local epidemiological picture and taking into account new
research evidence on efficiency and effectiveness. Also,
there is a need to include innovation in health system
products, processes, and delivery systems and to optimize
the performance of medical care through better understanding
causes and courses of HCV infection and also, treatment
consequences.
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